Over a period of 2 years, serum levels of 25-OH-D were measured 9 times in 88 relapsing-remitting MS patients included in a randomised trial of omega 3 fatty acids (the OFAMS study). In 92% of participants, the expanded disability status scale (EDSS) could be assessed 10 years later [1]. The overall mean 25-OH-D levels in the baseline period was 74.0. The median EDSS score increased from 2.0 at baseline to 2.5 at follow-up. Higher 25-OH-D was associated with significantly lower disability progression 10 years later. Change in EDSS score per 20-unit increase in 25-OH-D was -0.5 (P=0.01).
CSF as well as blood NfL holds promise as a biomarker of disease course and treatment response in relapsing-remitting MS. The predictive value of NfL levels for cognitive impairment in patients with secondary progressive MS has now also been explored [2]. In consented participants of the EXPAND trial of siponimod, high baseline NfL levels were associated with an elevated risk for cognitive worsening, regardless of focal lesion activity. Patients with Gd+ T1 lesions at baseline had a more pronounced risk of cognitive worsening. A previous finding in the EXPAND study was that high NfL levels at baseline correlated with low baseline Symbol Digit Modalities Test (SDMT) scores. In 1,397 patients, high baseline NfL levels were associated with a 41.4% higher risk of reaching a 6-month confirmed worsening on SDMT (6mCWSDMT) by 4-points from baseline, compared to patients with low NfL levels. This higher risk was especially pronounced in patients with Gd+ T1 lesions at baseline (n=296/1,397; see Table).
Table: Risk of reaching 6-month confirmed worsening on Symbol Digit Modalities Test [2]
A study assessing long-term predictors of global cortical thinning found that patients with more severe early cortical pathology and demonstrating a faster rate of cortical thinning are at higher risk of converting to secondary progressive MS [3]. A total of 219 relapsing-remitting MS patients were followed for 7.9 mean years; 59 (27%) patients converted to secondary progressive MS. In a multivariate model, more severe global cortical thinning loss over time was independently predicted by:
- larger accumulation of cortical lesions (OR=3.47; P=0.01);
- faster cortical thinning during the first 2 years (OR=1.43; P=0.001);
- ≥3 early relapses (OR=8.41; P<0.001).
The authors concluded that early focal cortical damage and early relapses affect the severity of grey matter loss in the long term, and can be used to identify groups potentially benefiting from early aggressive treatment.
- Wesnes K, et al. EAN 2019, EPO3216.
- Kuhle J, et al. EAN 2019, EPO2201.
- Scalfari A, et al. EAN 2019, EPR2085.
Posted on
Previous Article
« Atogepant efficacious, safe, and well-tolerated for migraine prevention Next Article
No disease-modifying effect of levodopa/carbidopa in Parkinson’s »
« Atogepant efficacious, safe, and well-tolerated for migraine prevention Next Article
No disease-modifying effect of levodopa/carbidopa in Parkinson’s »
Table of Contents: EAN 2019
Featured articles
Letter from the Editor
Alzheimer’s Disease and other Dementias
A necessary shift of focus to the earlier stages of Alzheimer’s
Antipsychotics increase mortality regardless of comorbidity
Epilepsy
Neuroinflammatory pathways as biomarkers and treatment targets
Long-term effect of recurrent febrile seizures
Migraine
The role of neurogenic inflammation in migraine
Multiple Sclerosis
Treating MS from disease onset
Randomised and observational studies comparing treatments
Autologous haematopoietic stem cell transplantation
Neuromuscular Disorders
Parkinson's Disease and other Movement Disorders
Inflammation may change the course of Parkinson’s disease
Opicapone: follow-up on the BIPARK I and II trials
Epigallocatechin gallate does not modify MSA progression
Stroke
Thrombo-inflammation during ischaemia/reperfusion
Related Articles
March 25, 2021
Retinal damage may signal risk for stroke and dementia
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy